Translational Bioengineering: Angelika Fretzen, COO & Tech Translation Director at the Wyss Institute, on BIOSNext
The BIOS Podcast by Alix Ventures features experts and thought leaders in healthcare & life sciences. We bring you cutting-edge insights from executives, investors, founders, scientists, academics, and more. BIOS is a community of early stage healthcare and life sciences founders and investors. It is anchored by Alix Ventures, a San Francisco-based venture fund that invests in early stage healthcare and life sciences companies.
Angelika Fretzen is the Wyss Institute’s Chief Operating Officer & Technology Translation Director, applying her technology and entrepreneurial business development experience to steer the Institute’s technology translation engine in diverse areas of research and technology development and to integrate the Institute’s business development and technology commercialization efforts. She earned her Ph.D. in organic chemistry at the University of Geneva, Switzerland, and gained postdoctoral experience in the laboratory of Professor Gregory Verdine at Harvard University. Following her academic training, Angelika pursued her M.B.A. at Suffolk University, Boston, and subsequently held leadership positions at Ironwood Pharmaceuticals, and most recently at Catabasis Pharmaceuticals in Cambridge, MA, where she was Senior Vice President of Product Development. Her industry experience enabled her to gain a deep understanding of the processes involved in developing and de-risking therapeutic products from pre-clinical stages to the clinical market, including the regulatory approval process. She also serves on the Board of Directors of Bridgewell, a health and human services non-profit organization serving a wide range of constituents in day programs, residential housing and clinical services.